Explore

Trump Administration Faces Internal GOP Conflict Over Health Policies and Farm Bill

Trump Administration Faces Internal GOP Conflict Over Health Policies and Farm Bill

The Trump administration is experiencing internal conflict with Health and Human Services Secretary Robert F. Kennedy Jr. and the 'Make America Healthy Again' (MAHA) campaign over several key issues. This discord is primarily centered around pesticide regulations and the nomination of a new surgeon general. The recently passed Farm Bill, which includes provisions on pesticide regulation, has sparked significant debate within the GOP. MAHA supporters, including influential activists, have expressed dissatisfaction with the administration's policies, which they feel contradict the health-first approach advocated by Kennedy. The nomination of Nicole Saphier as surgeon general, replacing Casey Means, has further fueled tensions, as MAHA activists view this as a breach of promises made to them.

MAHA Campaign Clashes with Trump Administration Over Health Policies, Causing GOP Tensions

MAHA Campaign Clashes with Trump Administration Over Health Policies, Causing GOP Tensions

The Trump administration is experiencing internal conflict with Health and Human Services Secretary Robert F. Kennedy Jr. and his 'Make America Healthy Again' (MAHA) campaign. The discord centers around recent policy decisions, particularly concerning pesticide regulations and the nomination of a new surgeon general. The MAHA campaign, which emphasizes health-first policies, is at odds with some of the administration's 'America-first' initiatives, leading to a divide within the Republican Party. This tension is exacerbated by the upcoming U.S. midterm elections, as MAHA supporters express dissatisfaction with the administration's stance on health-related issues.

Legal Challenge to CMS Hemp Strategy Raises Concerns Over FDA Authority

Legal Challenge to CMS Hemp Strategy Raises Concerns Over FDA Authority

A federal lawsuit in the U.S. District Court for the District of Columbia is challenging the legality of the Centers for Medicare & Medicaid Services' (CMS) Beneficiary Engagement Incentive (BEI) model. This program allows the furnishing of certain hemp-derived cannabinoid products to Medicare beneficiaries without U.S. Food and Drug Administration (FDA) approval. The case, Smart Approaches to Marijuana (SAM) et al. v. Robert F. Kennedy Jr. et al., questions whether CMS can introduce cannabinoid products into Medicare-connected environments without the traditional FDA approval process. Critics argue that this policy shift undermines the established sequence of science, clinical trials, FDA approval, and coverage integration, potentially signaling that clinical evidence is optional.

Warned off vaccine actions, Kennedy seeks quick health wins ahead of midterms

Warned off vaccine actions, Kennedy seeks quick health wins ahead of midterms

By Yasmeen Abutaleb and Bo Erickson WASHINGTON, May 4 (Reuters) - U.S. Health Secretary Robert F.

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

This Day in History: Alan Freed Brought Rock to ABC

This Day in History: Alan Freed Brought Rock to ABC

In 1957, the American television landscape was introduced to a groundbreaking show called 'The Big Beat.' Hosted by Alan Freed, this music and danc...

Edgewood Lifts Fireworks Ban Ahead of July 4th Celebrations

Edgewood Lifts Fireworks Ban Ahead of July 4th Celebrations

The city of Edgewood in Pierce County has lifted its ban on fireworks following a 5-2 vote by the city council. The decision, effective from April 22, 2026, aligns the city with state regulations, allowing residents to use fireworks under state guidelines. The move comes as part of preparations for the 250th anniversary of America's independence on July 4th. The council's decision reflects a shift in public opinion, with more members now opposing the ban compared to previous years. The ban, initially imposed in 2023, was aimed at reducing fire risks and disturbances.

Federal Court Reviews CMS Hemp-Marijuana Reimbursement Program Amid Legal Challenge

Federal Court Reviews CMS Hemp-Marijuana Reimbursement Program Amid Legal Challenge

A federal district court in Washington, D.C. is reviewing a legal challenge against the Centers for Medicare & Medicaid Services (CMS) regarding its hemp-marijuana reimbursement program. The case, Smart Approaches to Marijuana v. Kennedy, questions whether CMS exceeded its authority by implementing a reimbursement incentive for hemp-derived cannabinoid products without public rule-making or FDA involvement. The program, which began on April 1, 2026, allows participating organizations to provide these products to Medicare beneficiaries, with potential reimbursements of up to $500 per beneficiary annually. The court is considering whether the CMS's actions align with statutory requirements and if the program can proceed without traditional regulatory processes.

FDA Appoints Katherine Szarama as Acting CBER Director Amid Leadership Changes

FDA Appoints Katherine Szarama as Acting CBER Director Amid Leadership Changes

The U.S. Food and Drug Administration (FDA) has appointed Katherine Szarama as the acting director of the Center for Biologics Evaluation and Research (CBER). Szarama, who previously served as deputy under Vinay Prasad, steps into the role following Prasad's departure. Prasad's tenure was marked by controversy, particularly surrounding the handling of Sarepta Therapeutics' Elevidys, a gene therapy for Duchenne muscular dystrophy, which faced shipment halts after patient deaths. Szarama's background includes roles at the Centers for Medicare and Medicaid Services and the Advanced Research Projects Agency for Health. Her appointment is part of a broader pattern of temporary leadership within the Department of Health and Human Services (HHS), as the agency navigates ongoing challenges and transitions.

President Trump Nominates Dr. Nicole Saphier for Surgeon General Amidst Vaccine Controversy

President Trump Nominates Dr. Nicole Saphier for Surgeon General Amidst Vaccine Controversy

President Trump has nominated Dr. Nicole Saphier, a radiologist and former Fox News Channel contributor, for the role of surgeon general. This marks his third attempt to fill the position, which is responsible for promoting health and wellness in the United States. Saphier, who directs breast imaging at Memorial Sloan Kettering Monmouth, is expected to face scrutiny over her qualifications and views on vaccines. Her nomination follows the withdrawal of Trump's previous picks, Dr. Casey Means and Dr. Janette Nesheiwat, due to various controversies. Saphier's nomination is anticipated to be more acceptable to Republican lawmakers, although she will still face questions from the Senate Health, Education, Labor and Pensions Committee.

Federal Judge Questions Legality of Hemp-Marijuana Reimbursement Program for Medicare

Federal Judge Questions Legality of Hemp-Marijuana Reimbursement Program for Medicare

A federal district court in Washington, D.C. is reviewing a case challenging the Centers for Medicare & Medicaid Services (CMS) over its hemp-marijuana reimbursement program. The case, Smart Approaches to Marijuana v. Kennedy, questions whether CMS exceeded its authority by implementing a program that reimburses cannabinoid products for Medicare beneficiaries without public rule-making or FDA involvement. The program, which began on April 1, 2026, allows organizations to provide hemp-derived products and receive up to $500 per beneficiary annually. The court is considering whether the program's implementation without FDA validation or public input violates statutory requirements.

Supreme Court Asked to Maintain Mail Access for Abortion Drug Mifepristone Amid Legal Challenges

Supreme Court Asked to Maintain Mail Access for Abortion Drug Mifepristone Amid Legal Challenges

The Supreme Court is being petitioned to keep the abortion drug mifepristone available by mail following a lower court's decision to block its distribution. This request comes after the 5th U.S. Circuit Court of Appeals temporarily reinstated a requirement for in-person prescriptions, a rule previously eliminated by the Biden administration. Louisiana, supported by several Republican-led states, argues that mailing the drug facilitates nearly 1,000 illegal abortions monthly and poses health risks such as sepsis and hemorrhaging. Danco Laboratories, a manufacturer of mifepristone, has filed an emergency appeal, claiming the ruling causes confusion and disrupts medical decisions. The case highlights ongoing legal battles over abortion access in the U.S., with the Supreme Court's decision potentially impacting the availability of mifepristone nationwide.